Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Fig. 1

MRI abdomen T2-hyperintense signal. a & b showing multiple metastatic lesions to the liver before the initiation of immunotherapy. c showing progression of the disease after 4 cycles of nivolumab. The largest lesion was 5.5 cm in the right hepatic lobe. d showing a mixed response after 4 cycles on ipilimumab/nivolumab

Back to article page